financetom
Business
financetom
/
Business
/
Inter Parfums Shares Decline After Q1 Net Sales Fall Short of Consensus
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Inter Parfums Shares Decline After Q1 Net Sales Fall Short of Consensus
Apr 25, 2024 11:23 AM

02:12 PM EDT, 04/25/2024 (MT Newswires) -- Inter Parfums ( IPAR ) shares were down nearly 9% in recent trading Thursday, a day after it reported Q1 net sales of $324 million that were up from $312 million a year earlier, but missed the consensus polled by Capital IQ of $334.2 million.

European-based operations net sales remained nearly flat year over year, while US-based sales for the quarter ended March 31 were $96 million, up 18% from $82 million a year earlier.

The company reaffirmed its net sales guidance for the full year of $1.45 billion. Analysts surveyed by Capital IQ expect $1.45 billion.

Price: 119.18, Change: -11.34, Percent Change: -8.69

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Amazon.com's Prime Big Deal Days to Take Place in October
Amazon.com's Prime Big Deal Days to Take Place in October
Sep 17, 2024
06:34 AM EDT, 09/17/2024 (MT Newswires) -- Amazon.com ( AMZN ) said Tuesday that its Prime Big Deal Days will take place on Oct. 8 and Oct. 9, offering major savings to its members. Prime members can get exclusive holiday discounts on various items including clothes, accessories and electronics, with deals dropping as often as every 5 minutes during select...
Merck's Lung Cancer Drug Meets Primary Endpoint in Late-Stage Study
Merck's Lung Cancer Drug Meets Primary Endpoint in Late-Stage Study
Sep 17, 2024
06:38 AM EDT, 09/17/2024 (MT Newswires) -- Merck ( MRK ) said Tuesday that a late-stage study of its experimental therapy, patritumab deruxtecan, in certain patients with a type of non-small cell lung cancer, has met its primary endpoint. The study found that patients treated with patritumab deruxtecan had a statistically significant improvement in progression-free survival compared with standard chemotherapy....
Vortex Metals Releases Surface Sampling Results From Illapel Project in Chile
Vortex Metals Releases Surface Sampling Results From Illapel Project in Chile
Sep 17, 2024
06:34 AM EDT, 09/17/2024 (MT Newswires) -- Vortex Metals ( VMSSF ) on Tuesday released the results from the surface sampling program it conducted at the Illapel Copper Project in Chile in July. Thirteen surface samples were collected and preliminary results indicate significant copper mineralization, with eight out of the 13 samples revealing significant copper mineralization above 1% copper, the...
Daiichi Sankyo-Merck's cancer drug meets main goal in late-stage trial
Daiichi Sankyo-Merck's cancer drug meets main goal in late-stage trial
Sep 17, 2024
Sept 17 (Reuters) - Daiichi Sankyo ( DSKYF ) and Merck ( MRK ) said on Tuesday that their drug, patritumab deruxtecan, met the main goal in a late-stage study in some patients with a type of lung cancer. The drug helped patients live significantly longer without their cancer progressing, compared with patients who were treated with chemotherapy, the companies...
Copyright 2023-2026 - www.financetom.com All Rights Reserved